SCHEDULE 13G/A: Wellington Management Discloses 3.38% Stake in Edwards Lifesciences

Wellington Management Group LLP and its affiliates reported a 3.38% beneficial ownership stake in Edwards Lifesciences Corporation as of June 30, 2025.

Summary

• Wellington Management Group LLP, along with Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, collectively reported beneficial ownership of 19,826,483 shares of Edwards Lifesciences Corporation common stock.
• This represents 3.38% of the class of securities.
• The reporting entities hold shared voting power over 18,601,111 shares and shared dispositive power over 19,826,483 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previous ownership disclosure.
• The shares are owned of record by clients of the Wellington Investment Advisers, with Wellington Management Group LLP acting as the parent holding company.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership disclosure (Schedule 13G Amendment) and does not contain information that inherently indicates a positive or negative sentiment regarding the company's performance or strategic direction.

Positives

• The filing confirms continued investment by a major institutional investor, Wellington Management, in Edwards Lifesciences Corporation.

Negatives

• The current beneficial ownership stake of 3.38% is below the 5% threshold that typically triggers an initial Schedule 13G filing, which could imply a reduction from a previously higher stake, though the filing does not explicitly state this.

Future Outlook

NA

Industry Context

Wellington Management is a globally recognized investment firm. Their continued, albeit potentially adjusted, stake in Edwards Lifesciences, a leader in medical technologies, reflects ongoing institutional interest in the healthcare and medical device sectors. Such disclosures provide transparency into significant institutional holdings.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership stake of a major institutional investor, Wellington Management, in Edwards Lifesciences Corporation.

Key Dates

Keywords

Edwards Lifesciences Corporation, Wellington Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Medical Technology